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Abstract
Background: It has been challenging to determine the true clinical impact of Acinetobacter spp., due to the predilection
of this pathogen to colonize and infect critically ill patients, who often have a poor prognosis. The aim of this study
was to assess whether Acinetobacter spp. bacteremia is associated with lower survival compared with bacteremia
caused by other pathogens in critically ill patients.
Methods: This study was performed at Hospital das Clínicas, University of São Paulo, Brazil. There are 12 intensive
care units (ICUs) in the hospital: five Internal Medicine ICUs (emergency, nephrology, infectious diseases and
respiratory critical care), three surgical ICU (for general surgery and liver transplantion), an Emergency Department
ICU for trauma patients, an ICU for burned patients, a neurosurgical ICU and a post-operative ICU. A retrospective
review of medical records was conducted for all patients admitted to any of the ICUs, who developed bacteremia
from January 2010 through December 2011. Patients with Acinetobacter spp. were compared with those with other
pathogens (Klebsiella pneumoniae, Staphylococcus aureus, Enterobacter spp., Enterococcus spp., Pseudomonas aeruginosa).
We did a 30-day survival analysis. The Kaplan-Meier method and log-rank test were used to determine the overall
survival. Potential prognostic factors were identified by bivariate and multivariate Cox regression analysis.
Results: One hundred forty-one patients were evaluated. No differences between patients with Acinetobacter spp. and
other pathogens were observed with regard to age, sex, APACHE II score, Charlson Comorbidity Score and type of
infection. Initial inappropriate antimicrobial treatment was more frequent in Acinetobacter bacteremia (88 % vs 51 %).
Bivariate analysis showed that age > 60 years, diabetes mellitus, and Acinetobacter spp. infection were significantly
associated with a poor prognosis. Multivariate model showed that Acinetobacter spp. infection (HR = 1.93, 95 % CI:
1.25–2.97) and age > 60 years were independent prognostic factors.
Conclusion: Acinetobacter is associated with lower survival compared with other pathogens in critically ill patients
with bacteremia, and is not merely a marker of disease severity.
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Background
It has been challenging to determine the true clinical
impact of Acinetobacter spp., due to the predilection of
this pathogen to colonize and infect critically ill patients,
who often have a poor prognosis irrespective of secondary
infective complications [1].
Some investigators found high mortality rates in intensive
care unit (ICU) patients with Acinetobacter bacteremia:
61.6 % in Israel [2], 65.5 % in Brazil [3] and 43.4 % in the
United States [4].
When outcomes from Acinetobacter baumannii were
compared directly with those of patients who had
bacteremia caused by other organisms, a significantly
higher mortality was noted for A. baumannii [2, 5].
However, none of these studies used a formal, standardized
method to adjust for severity of illness or comorbidities,
such as APACHE or Charlson score. Another study
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involving trauma patients showed no difference in mor-
tality comparing infections by Acinetobacter and by
other pathogens [6]. Tonacio et al. [7] found 30 % of
mortality in patients with Acinetobacter spp. infections
and trauma was a marker of good prognosis in those
patients.
Some studies observed growing resistance among other
gram-negative and gram-positive pathogens that cause
healthcare-associated infections. Rice [8] reported these as
the “ESKAPE” pathogens: Enterococcus faecium, Staphylo-
coccus aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Enterobacter species
[8, 9]. These pathogens cause an increasing number of
healthcare-associated infections with significant morbidity
and mortality, with are often associated with ICU
admission [10].
The aim of this study was to evaluate whether bacteremia
caused by Acinetobacter spp. was associated with lower sur-
vival compared with bacteremia caused by other prevalent
pathogens in critically ill patients.
Methods
This study was performed at Hospital das Clínicas,
University of São Paulo, Brazil, a 2200-bed tertiary-
care teaching hospital. There are 12 ICUs in the hospital;
five Internal Medicine ICUs (emergency, nephrology,
infectious diseases and respiratory critical care), three
surgical ICU (for general surgery and liver transplantion),
an Emergency Department ICU for trauma patients, an
ICU for burned patients, a neurosurgical ICU and a post-
operative ICU.
A retrospective review of medical records was conducted
for all patients admitted to the ICUs who developed
bacteremia from January 2010 through December 2011.
The inclusion of the patients was based on notifications of
nosocomial infections made by the Hospital Infection
Control Team according to CDC/NHSN criteria [11].
All hospitalized patients with bacteremia by the selected
pathogens were included in the study if the blood cultures
were obtained > 48 h after admission to the ICU. In pa-
tients with recurrent bacteremia, only the first episode
was included. Polymicrobial infections were excluded.
Patients with Acinetobacter spp. bacteremia were com-
pared with patients with bacteremia caused by other path-
ogens (Klebsiella pneumoniae, Staphylococcus aureus,
Enterobacter spp., Enterococcus spp., Pseudomonas aerugi-
nosa). We selected these agents for comparison, as they
were healthcare-associated pathogens of epidemiologic
importance, had high antibiotic resistance rates, and were
the predominant healthcare-associated pathogens in the
hospital.
We evaluated prognostic factors associated with mor-
tality. The following variables were assessed: sex; age;
APACHE II score [12] on admission to ICU; use of
invasive devices and antimicrobials after the diagnosis of
bacteremia; initial site of infection and treatment; time
elapsed from admission in the ICU to diagnosis of
bacteremia; Pitt Bacteremia Score [12]; presence of
septic shock; and number of organ failures. Acute organ
failures (cardiovascular, respiratory, renal, hematologic
or central nervous system) were defined using the defini-
tions of Zimmerman et al. [13]. The patients’ underlying
diseases analyzed were: diabetes mellitus, liver cirrhosis,
cancer, transplant recipient, HIV infection, chronic renal
disease, obstructive pulmonary disease, trauma, and sys-
temic arterial hypertension. We also analyzed the Charlson
Comorbidity Score [14].
Bacteremias were classified as primary and secondary
bloodstream infections. Primary bloodstream infections
were those associated with the use of a central line or
those with an unknown or unclear initial site. Secondary
bloodstream infections were regarded as those with a clear
source of bacteremia other than a central line. Sources of
secondary bacteremia were identified by cultures of
samples (urine, tracheal secretions, intra-abdominal
samples, etc.) obtained from distant sites that yielded
the same pathogen with an identical resistance pattern.
Distant sites were sites where an infection was diag-
nosed other than a central line (pneumonia, surgical
site, urinary tract, skin and soft tissue, others).
Antibiotic treatment was deemed initial appropriate
antibiotic treatment (IAAT) if the initially prescribed anti-
biotic regimen was active against the identified pathogen,
based on in vitro susceptibility testing, and administered
within two days following the blood culture collection. All
other regimens were classified as initial inappropriate anti-
biotic treatment (IIAT).
Microbiology
The clinical microbiology laboratory made the identifi-
cation and antimicrobial susceptibility test of the se-
lected pathogens using VITEK 2® (bioMerieux VITEK,
Hazelwood, MO, USA). The breakpoints were those de-
fined by the Clinical and Laboratory Standards Institute
(CLSI) [15, 16].
The automatic identification method VITEK 2®
(bioMerieux VITEK, Hazelwood, MO, USA) showed the
results of Acinetobacter as Acinetobacter baumannii-
calcoaceticus complex. This complex includes other
pathogenic species besides Acinetobacter baumannii,
such as A. calcoaceticus, A. tjernbergiae (sp. 3), A.
ursingii (sp.13). As the isolates were not available for
further identification, we chose to refer to the micro-
organism as Acinetobacter spp.
Data analysis
We initially conducted a descriptive analysis comparing
patients with Acinetobacter spp. bacteremia and patients
Leão et al. BMC Infectious Diseases  (2016) 16:386 Page 2 of 8
with bacteremia caused by other pathogens. Baseline
characteristics and outcomes were described using sum-
mary (mean, standard deviation, median, minimum and
maximum) for quantitative variables and absolute and
relative frequencies for qualitative variables.
We did a 30-day survival analysis. For overall survival
time, we estimated median survival time according to the
characteristics of interest using the Kaplan-Meier function
and compared survival rates among the categories using
the log-rank test. The bivariate Cox regression was chosen
to calculate the hazard ratio (HR) in survival analysis, with
a 95 % confidence interval.
It was estimated the multiple Cox regression model
with the variables with descriptive level in bivariate tests
less than 0.10 (p <0.10) and considered with biological
plausibility. The tests were done at 5 % significance level.
In the case of variables that we considered measured
similar characteristics, only one variable was included in
the model. Statistical analyses were performed using
SPSS (Version 19.0).
Results
Three hundred forty-nine patients presented with the
selected pathogens bacteremia during the 2-year study
period (128 Acinetobacter spp., 55 Klebsiella pneumo-
niae, 40 Pseudomonas aeruginosa, 33 Enterobacter spp.,
49 Staphylococcus aureus and 44 Enterococcus spp.). 208
were excluded (99 had previous positive blood cultures, 68
had polymicrobial bacteremia, 27 had blood cultures ob-
tained ≤ 48 h after admission in the ICU, nine had incom-
plete records and five had unavailable records). Thus 141
patients were evaluated (59 with Acinetobacter spp.
bacteremia and 82 with bacteremia caused by other patho-
gens). The other pathogens were K. pneumoniae (n: 24),
S. aureus (n: 21), Enterobacter spp. (n: 15), Entero-
coccus spp. (n: 12) and P. aeruginosa (n: 10).
Patient characteristics by pathogen are detailed in
Table 1. No differences between Acinetobacter spp. and
other pathogens were observed with regard to age, sex,
APACHE II score, Charlson Comorbidity Score, dur-
ation of hospitalization in the ICU prior to bacteremia
and initial site of infection. A detailed analysis of back-
ground disease demonstrated no difference between the
two groups of patients. Chronic diseases were frequent,
including systemic arterial hypertension, cancer, chronic
renal disease, diabetes mellitus, solid organ transplants,
liver cirrhosis, trauma, obstructive pulmonary disease, HIV
infection and hematopoietic stem cell transplantation.
Both groups of pathogens presented high rates of
resistance to antibiotics. Most Acinetobacter spp. were
resistant to carbapenems (92 %) and susceptible to colis-
tin (95 %). Among the other pathogens, resistance to
methicillin was 71 % among Staphylococcus aureus; among
Enterococcus spp. 83 % were vancomycin-resistant (VRE);
and carbapenem resistance in Pseudomonas aeruginosa
was 30 %; 27 % in Klebsiella pneumoniae and 7 % in
Enterobacter spp. isolates.
Table 1 General characteristics of the entire cohort of patients
with bacteremia acquired in intensive care units
Acinetobacter spp. Other
pathogensa
Total
Number of patients (%) 59 (42) 82 (58) 141 (100)
Age
Mean (SD) 52 (18) 56 (16) 54 (17)
Median (overall range) 51 (17–92) 57 (18–85) 56 (17–92)
Male sex (%) 42 (71) 45 (55) 87 (62)
APACHE II score
Mean (SD) 20 (7) 20 (9) 20 (8)
Median (overall range) 20 (7–40) 19 (0–41) 19 (0–41)
CHARLSON score
Mean (SD) 3 (3) 3 (3) 3 (3)
Median (overall range) 2 (0–10) 3 (0–11) 3 (0–11)
Co-morbid condition (%)
Diabetes mellitus 14 (24) 17 (21) 31 (22)
Liver cirrhosis 18 (31) 10 (12) 28 (20)
Cancer 12 (20) 21 (26) 33 (23)
Solid organ transplant 17 (29) 13 (16) 30 (21)
Liver transplant 14 (24) 10 (12) 24 (17)
Kidney transplant 3 (5) 3 (4) 6 (4)
Hematopoietic cell
transplant
0 (0) 2 (2) 2 (1)
HIV infection 3 (5) 6 (7) 9 (6)
Chronic renal disease 15 (25) 16 (20) 31 (22)
Obstructive pulmonar
disease
4 (7) 8 (10) 12 (9)
Trauma 8 (14) 7 (9) 15 (11)
Systemic arterial
hypertension
19 (32) 37 (45) 56 (40)
ICU length of stay previous to bacteremia (in days)
Mean (SD) 11 (14) 17 (36) 15 (29)
Median (overall range) 7 (2–82) 9 (2–314) 8 (2–314)
Initial site of infection
Bloodstream 43 (73) 58 (71) 101 (72)
Pneumonia 3 (5) 11 (13) 14 (10)
Surgical site 5 (8) 6 (7) 11 (8)
Urinary tract 1 (2) 2 (2) 3 (2)
Skin and soft tissue 3 (5) 0 (0) 3 (2)
Other 4 (7) 5 (7) 9 (6)
SD standard deviation, ICU intensive care unit
aIncludes Klebsiella pneumoniae (n: 24), Staphylococcus aureus (n: 21),
Enterobacter spp. (n: 15), Enterococcus spp. (n: 12), Pseudomonas aeruginosa
(n: 10)
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Initial inappropriate antibiotic treatment was adminis-
tered to 88 % of patients with Acinetobacter spp. and
51 % of patients with other pathogens. More patients
with Acinetobacter spp. developed septic shock (81 % vs
52 %); needed mechanical ventilation within 24 h of the
diagnosis of bacteremia (88 % vs 66 %); and required a
central venous line (97 % vs 85 %). Patients with Acineto-
bacter spp. bacteremia had a higher mortality when
compared with bacteremia by the other pathogens (73 %
vs 50 %). The mean Pitt Bacteremia Score for Acineto-
bacter spp. was 7 (SD: 4) and for other pathogens was 4
(SD: 3). The mean number of organ failures for Acineto-
bacter spp. was 2.1 (SD: 1.2) and for other pathogens
was 1.67 (SD: 1.3). The cumulative survival curves of the
patients according to pathogen are shown in Figs. 1 and 2.
The bivariate analysis (Table 2) showed that age
>60 years, Acinetobacter spp. infection, and diabetes
mellitus were significantly associated with a poor
prognosis. The following variables also presented p <
0.10 in the bivariate analysis: sex; liver cirrhosis; ob-
structive pulmonary disease, and IIAT. The variables:
number of organ failures; septic shock; Pitt Bacteremia
Score (which evaluates the severity of the bacteremia),
mechanical ventilation and use of central venous line were
excluded from the bivariate and multivariate analyses
because they were considered intrinsically correlated with
the event death and not proper prognostic factors. We
verified that these factors, excluded from the multivariate
analysis, were statistically associated with the outcome,
except for use of central venous line (data not shown).
Most patients with diabetes mellitus were older than
60 years, thus the variable diabetes mellitus was also
not included in the multivariate analysis. Among the
cases of bacteremia by Acinetobacter spp. most re-
ceived IIAT (88 %) thus we did not enter this variable
into the model. Thus, in the model of Cox regression
analysis we evaluated the following variables: age
divided into the following strata: ≤ 60 years or >
60 years; sex; liver cirrhosis; obstructive pulmonary
disease; and Acinetobacter spp. bacteremia. The multi-
variate model showed that Acinetobacter spp. infec-
tion (HR: 1.93, 95 % CI 1.25–2.97) and age > 60 years
were statistically associated with mortality (Table 3).
Discussion
Our study was conducted to evaluate prognostic
factors, especially Acinetobacter spp. infection, in
patients with bacteremia acquired in ICU. We con-
cluded that patients who had Acinetobacter spp.
bacteremia presented a significantly worse prognosis,
independently of severity of the clinical condition and
other potential confounders. Another important as-
pect was the short period of time between Acineto-
bacter bacteremia and death.
The increase in the number of infections caused by
multidrug-resistant bacteria, especially gram-negative
bacilli, is one of the most important issues in modern
healthcare [17]. Among several gram-negative bacilli,
non-fermentative organisms such as Pseudomonas aeru-
ginosa and Acinetobacter baumannii are the most prob-
lematic because of their high frequency and wide
Fig. 1 Cumulative survival after episodes of Acinetobacter spp.
bacteremia and bacteremia caused by other pathogens. The curve was
illustrated with the Kaplan-Meier method (log-rank test, p = 0.005)
Fig. 2 Cumulative survival after episodes of Acinetobacter spp.
bacteremia and bacteremia caused by other gram-negative pathogens.
The curve was illustrated with the Kaplan-Meier method (log-rank
test, p = 0.033)
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Table 2 Bivariate analysis of prognostic factors of patients with bacteremia acquired in intensive care units
Variables Median survival time (days) 95 % CI HR 95 % CI Death/total (%) P
Age > 60 years
Yes 5 0.00–10.82 1.67 1.08–2.58 37/53 (70) 0.02
No 20 11.07–28.93 1 47/88 (53)
Sex
Male 9 4.32–13.69 1.49 0.95–2.35 56/87 (64) 0.08
Female 25 9.67–40.34 1 28/54 (52)
APACHE II Score > 20
Yes 10 3.48–16.52 1.11 0.72–1.70 39/60 (65) 0.64
No 15 5.10–24.9 1 45/81 (56)
CHARLSON Score > 3
Yes 15 1.78–28.22 1.18 0.76–1.84 31/48 (65) 0.46
No 11 5.32–16.68 1 53/93 (57)
Co-morbid condition
Diabetes mellitus
Yes 7 a 1.67 1.03–2.70 23/31 (74) 0.03
No 16 6.86–25.14 1 61/110 (55)
Liver cirrhosis
Yes 5 0.01–9.99 1.58 0.96–2.59 21/28 (75) 0.07
No 16 4.30–27.70 1 63/113 (56)
Cancer
Yes 18 0.00–39.72 0.87 0.52–1.46 18/33 (55) 0.59
No 10 5.01–14.99 1 66/108 (61)
Solid organ transplant
Yes 5 0.98–9.02 1.31 0.80–2.15 21/30 (70) 0.28
No 16 7.22–24.78 1 63/111 (57)
Hematopoietic stem cell transplant
Yes 7 a 0.87 0.12–6.26 1/2 (50) 0.89
No 11 4.21–17.79 1 83/139 (60)
HIV infection
Yes a a 0.61 0.22–1.66 4/9 (44) 0.33
No 10 4.12–15.88 1 80/132 (61)
Chronic renal disease
Yes 10 0.56–19.45 1.30 0.79–2.14 21/31 (68) 0.29
No 13 3.92–22.08 1 63/110 (57)
Obstructive pulmonary disease
Yes 8 0.00–21.58 1.73 0.92–3.26 11/12 (92) 0.09
No 12 3.85–20.15 1 73/129 (57)
Trauma
Yes a a 0.57 0.25–1.30 6/15 (40) 0.18
No 10 3.27–16.73 1 78/126 (62)
Systemic arterial hypertension
Yes 8 2.39–13.61 1.16 0.75–1.80 33/56 (59) 0.51
No 15 6.39–23.61 1 51/85 (60)
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spectrum of antimicrobial resistance. This leads to a limited
therapeutic armamentarium against them [18, 19]. At our
hospital, from January, 2010 through December 2011, 14 %
of all episodes of bacteremia were polymicrobial. Of all
monomicrobial episodes, most were caused by gram-
negative organisms. The rank order of the major patho-
gens shows that Acinetobacter spp. were the principal
organisms responsible for bacteremias (22 %), and most
of Acinetobacter spp. were resistant to carbapenems.
Administering appropriate initial antibiotic therapy is
essential in the treatment of septic patients [20] and is
associated with lower mortality rate in patients with
Acinetobacter spp. bacteremia [21, 22]. Our study found
that 92 % of the Acinetobacter spp. isolates were
carbapenem-resistant and, in most cases, colistin was
the only available antimicrobial agent to treat these
serious infections. The time required for identification
of Acinetobacter spp. by culture and for identifying car-
bapenem resistance was greater than the maximum
time (48 h) defined in the present study for beginning
the appropriate therapy.
Without microbiological information as a guide, only
12 % of patients with Acinetobacter spp. bacteremia re-
ceived effective drugs within 48 h, possibly contributing
to the high mortality rate in these patients. In the
bivariate analysis of prognostic factors, IIAT appears to
be associated with mortality, with a borderline significance
Table 2 Bivariate analysis of prognostic factors of patients with bacteremia acquired in intensive care units (Continued)
ICU length of stay previous to bacteremia > 8 days
Yes 20 8.90–31.10 0.78 0.51–1.21 37/65 (57) 0.27
No 9 5.20–12.80 1 47/76 (62)
Initial site of infection
Primary bloodstream
Yes 13 4.71–21.29 1.01 0.63–1.62 60/101 (59) 0.97
No 9 2.98–15.02 1 24/40 (60)
Pneumonia
Yes 8 0.67–15.33 1.32 0.68–2.56 10/14 (71) 0.41
No 13 4.88–21.13 1 74/127 (58)
Surgical site
Yes 13 4.22–21.78 1.22 0.58–2.52 76/130 (58) 0.60
No 9 3.53–14.47 1 8/11 (73)
Urinary tract
Yes a a 0.05 0.00–10.63 0/3 (0) 0.27
No a a 1 84/138 (61)
Skin and soft tissue
Yes 1 a 1.40 0.34–5.71 2/3 (67) 0.64
No 12 5.27–18.73 1 82/138 (59)
Acinetobacter spp.
Yes 2 0.00–4,51 1.85 1.21–2.85 43/59 (73) 0.005
No 24 19.42–28,58 1 41/82 (50)
IIAT
Yes 9 4.46–13.54 1.53 0.98–2.36 50/73 (68) 0.057
No 24 7.06–40.95 1 34/68 (50)
CI Confidence interval, HR Hazard Ratio, ICU intensive care unit, IIAT initial inappropriate antimicrobial treatment
aNot possible to calculate median time and confidence interval
Table 3 Multivariate model of prognostic factors of patients
with bacteremia acquired in intensive care units
Crude HR 95 % CI Adjusted HR 95 % CI P
Acinetobacter spp. 0.003
No 1 1
Yes 1.85 1.21–2.85 1.93 1.25–2.97
Age 0.012
≤ 60 years 1 1
> 60 years 1.67 1.08–2.58 1.75 1.13–2.70
CI Confidence interval, HR Hazard Ratio
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(p = 0.057). In the multivariate model, Acinetobacter
was associated with poor prognosis, but IIAT may have
a part in explaining why Acinetobacter cases had a
worse prognosis.
Our data show the high mortality of infections caused
by carbapenem-resistant Acinetobacter spp. Based on
our findings, we suggest that early initiation of treatment
including colistin is important to improve survival in
ICUs where infections by these isolates are frequent.
Our results also suggest the need for more effective
antibiotic stewardship programs to avoid unnecessary
treatment with broadly active antibacterial therapy that
selects for carbapenem resistance. New infection pre-
vention strategies and technologies are needed against
these infections.
Some studies suggest that Acinetobacter spp. are op-
portunistic pathogens that affect patients who are more
likely to die because of the severity of their prior
disease [23–25]. Blot et al. [26] compared Acinetobacter
baumannii bacteremia with matched controls and found
that Acinetobacter baumannii was not an independent pre-
dictor for mortality. In another single-center experience [6],
Acinetobacter baumannii infection, including multidrug-
resistant isolates, the impact on mortality in a cohort of
trauma patients was not conclusive. However, Acineto-
bacter baumannii infection was associated with a longer
intensive care unit stay and a higher rate of organ failures.
In a review article, Peleg et al. [1] showed that the
studies on prognosis of Acinetobacter infections lacked
an adequate evaluation of the patients’ severity of under-
lying condition. Thus, in our study, we used formal and
standardized methods to adjust for severity of illness
and comorbidities (APACHE II and Charlson Score).
Surprisingly, these variables and the underlying diseases
were not significant prognostic factors. These findings
support that the high mortality caused by this serious
healthcare-associated pathogen cannot be attributed
only to underlying conditions and that Acinetobacter
infections are not merely markers of the severity of the
patients’ clinical condition.
The median survival of the Acinetobacter group was
only two days, thus suggesting the severity of the infec-
tion. In our study, the median of Pitt Bacteremia Score
was higher in the Acinetobacter spp. group. Rhee et al.
suggested that the Pitt bacteremia score is an excellent
tool for assessing not only crude mortality, but also mor-
tality that is attributed to sepsis in ICU-admitted pa-
tients [12].
Some investigators found high mortality rates in ICU
patients with Acinetobacter bacteremia (43.4 to 61.6 %)
[2–4]. Virulence factors and genotypes of Acinetobacter
may have an important role in differences in mortality.
Few clinical data are available on the relationship between
genospecies and outcome of Acinetobacter bacteremia.
Park et al. [27] compared the clinical features, antimicro-
bial resistance, and outcome of bacteremia caused by
Acinetobacter baumannii versus non-baumannii of the
Acinetobacter calcoaceticus–baumannii (ACB) complex.
The study found that the species, rather than the anti-
biotic resistance, affected mortality, in accordance with
other studies [28, 29]. Peleg et al. suggested that in vitro
and in vivo virulence characteristics differed among indi-
vidual strains of the ACB complex [30], which provides
further evidence of the impact of genospecies on the out-
come of Acinetobacter bacteremia. In our retrospective
study, we could not identify these factors, but the evalu-
ation of species and virulence factors in future epidemio-
logical and clinical studies of Acinetobacter infections may
be important.
Several limitations of this study are noteworthy. Because
it is a single-center study, our findings may be attributable
to institution-specific variables and may not reflect the
epidemiology of different centers or geographical areas.
The study was retrospective and some patients were
excluded because of incomplete data. Molecular identifi-
cation of the isolates was not performed to identify the
genomic species of Acinetobacter.
Conclusions
Our study adds to the existing evidence and the results
support that Acinetobacter is associated with lower
survival compared with other pathogens in critically ill
patients with bacteremia, and is not merely a marker
of disease severity.
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